Antibacterial Drivers of Resistance

Zhanel, George G.

doi:10.2165/00151829-200504001-00005

Cited by 6 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clarithromycin was chosen because, when compared with other macrolides, it is preferentially concentrated in the lung epithelial lining fluid (28, 29), it may be less likely to contribute to antimicrobial resistance than other members of the macrolide family (30, 31), its side effect profile with extended treatment period has been described (32, 33), it is unlikely to significantly alter fluticasone pharmacokinetics (34), and it has been previously used in asthma (7). However, it is possible that the antimicrobial or anti-inflammatory effects might have been greater had another member of the macrolide class been chosen.…”

Section: Discussionmentioning

confidence: 99%

A trial of clarithromycin for the treatment of suboptimally controlled asthma

Sutherland

King

Icitovic

et al. 2010

Journal of Allergy and Clinical Immunology

125

105

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A trial of clarithromycin for the treatment of suboptimally controlled asthma

Sutherland

King

Icitovic

et al. 2010

Journal of Allergy and Clinical Immunology

125

105

View full text Add to dashboard Cite

show abstract

Clarithromycin extended-release in community-acquired respiratory tract infections

Williams

Bishai

2005

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Clarithromycin extended-release (ER) is a second-generation macrolide with bactericidal activity against a broad group of pathogens. It allows for convenient once-daily dosing (2 x 500 mg/day), and has less severe adverse effects than the immediate-release (IR) formulation of the drug, which may result in improved patient compliance. Clarithromycin ER has been approved for the treatment of community-acquired pneumonia, acute maxillary sinusitis and acute bacterial exacerbation of chronic bronchitis. In comparison to the IR formulation, clarithromycin ER demonstrates prolonged absorption from the gastrointestinal tract, allowing for once-daily dosing with improved gastrointestinal tolerability. Various double-blind, randomised clinical trials and group studies have found clarithromycin ER to be an efficacious treatment option, comparable with clarithromycin IR, or its other competitors.

show abstract

Antibiotic resistance associated with veterinary drug use in fish farms

Sørum¹

Improving Farmed Fish Quality and Safety

View full text Add to dashboard Cite

Antibacterial Drivers of Resistance

Cited by 6 publications

References 1 publication

A trial of clarithromycin for the treatment of suboptimally controlled asthma

A trial of clarithromycin for the treatment of suboptimally controlled asthma

Clarithromycin extended-release in community-acquired respiratory tract infections

Antibiotic resistance associated with veterinary drug use in fish farms

Contact Info

Product

Resources

About